{"title":"In vivo evidence for soluble Aβ oligomer-driven neuronal metabolic dysfunction in 5xFAD mice.","authors":"Chaynita Dashora, Anant Bahadur Patel","doi":"10.1186/s13195-026-02130-4","DOIUrl":"10.1186/s13195-026-02130-4","url":null,"abstract":"<p><strong>Background: </strong>Alzheimer's disease (AD) is characterized by the extracellular accumulation of amyloid-β (Aβ). Brain glucose hypometabolism, an early feature of AD, reflects neuronal metabolic dysfunction before the onset of clinical symptoms. While Aβ plaques are central to AD pathogenesis, the mechanisms by which different Aβ species, such as plaques and soluble oligomers, drive cell-type-specific neurometabolic dysfunction during disease progression remain poorly understood. This study evaluated the roles of different Aβ species in the neurometabolic trajectory across the presymptomatic, symptomatic, and advanced stages of AD.</p><p><strong>Methods: </strong>5xFAD and wild-type (WT) mice were investigated for cognitive performance, quantitative Aβ levels, and glial activation markers at 3, 6, and 12 months of age. Neuronal and astroglial metabolic activities were evaluated ex vivo using state-of-the-art <sup>1</sup>H-[<sup>13</sup>C]-NMR spectroscopy in conjunction with administration of [1,6-<sup>13</sup>C<sub>2</sub>]glucose and [2-<sup>13</sup>C]acetate, respectively.</p><p><strong>Results: </strong>The 5xFAD mice exhibited cognitive decline from 6 months that further deteriorated by 12 months. There was a marked increase in Aβ-plaque burden and soluble oligomers from 3 to 12 months of age. These mice showed a significant reduction in hippocampal glutamatergic (0.145 ± 0.031 vs. 0.172 ± 0.016 µmol/g/min, p = 0.035) and GABAergic neuronal metabolic activity (0.027 ± 0.006 vs 0.033 ± 0.003 µmol/g/min, p = 0.028) as early as 3 months of age, with similar reductions observed in the cerebral cortex. The neurometabolic impairments further aggravated with age. Astrocytic metabolic activity was not significantly changed till 6 months but was increased at 12 months in 5xFAD mice in both the cerebral cortex (0.101 ± 0.014 vs. 0.084 ± 0.006 µmol/g/min, p = 0.011) and hippocampus (0.103 ± 0.006 vs. 0.089 ± 0.012 µmol/g/min, p = 0.011). The increase in astrocytic metabolic activity paralleled reactive gliosis, suggesting a shift from early neuronal metabolic impairment to heightened astroglial metabolic activity and inflammatory glial responses during the advanced AD stage. Notably, Aβ<sub>40</sub> oligomers exhibited a greater sensitivity to impairment in neuronal glucose oxidation and cognitive function than Aβ<sub>42</sub> oligomers or fibrillar plaques.</p><p><strong>Conclusions: </strong>These findings delineate a sequential neurometabolic cascade during AD progression, characterized by early neuronal glucose hypometabolism, subsequent cognitive decline linked to soluble Aβ<sub>40</sub> oligomers, and late-stage astroglial metabolic activation. Collectively, these results suggest that soluble Aβ<sub>40</sub> oligomers exhibit the greatest sensitivity to neurometabolic and cognitive impairment during AD.</p>","PeriodicalId":7516,"journal":{"name":"Alzheimer's Research & Therapy","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13700184/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148417964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Benjamin Kröger, Maria M Ekblom, Hui-Xin Wang, Charlotta Thunborg, Miia Kivipelto, Rui Wang
{"title":"Activity profiles and their associations with transitions between fall and dementia: findings from a multistate time-to-event analysis.","authors":"Benjamin Kröger, Maria M Ekblom, Hui-Xin Wang, Charlotta Thunborg, Miia Kivipelto, Rui Wang","doi":"10.1186/s13195-026-02140-2","DOIUrl":"10.1186/s13195-026-02140-2","url":null,"abstract":"<p><strong>Background: </strong>The potential link between data-driven classifications of individuals' activity profiles and the occurrence of fall and dementia, including within-person transitions from dementia- or fall-only states to their co-occurrence over time, remains unclear.</p><p><strong>Method: </strong>To examine whether distinct activity profiles were associated with the risk of fall, dementia, and their transitions over time in middle-aged and older adults, this prospective longitudinal study included 288,287 adults (53.6% women) aged 40-69 years at baseline (2006-2010) from the UK Biobank. Latent class analysis was used to classify participants into distinct activity profiles based on self-reported physical activity, transportation, work, social, and sleep behaviours. Incident fall and dementia were identified through linkage to health records and the death registry up to December 2022. Multistate time-to-event analysis was conducted to examine the associations between activity profiles and the risks of fall, dementia, and their transitions over time.</p><p><strong>Results: </strong>Based on various activity levels and work status, participants were categorized into four groups: active-non-working (29.2%), inactive-non-working (14.4%), active-working (26.7%), and inactive-working (29.7%). Of them, 19,753 (6.85%) experienced a fall injury, and 4,407 (1.53%) developed dementia over an average follow-up of 13.4 years. The inactive-non-working group showed the highest risk of both fall and dementia (HR<sub>range</sub>: 1.45-2.38) over 13.4 years. In the non-working groups, where fall and dementia occurred most often, the inactive profile was linked to a higher risk of both fall and dementia, and to an increased likelihood of transitioning between the two. Transitions from dementia to subsequent fall were associated with insufficient physical activity, whereas transitions from fall to subsequent dementia were linked to social isolation, particularly living alone and frequent loneliness. In the working groups, no differences in fall or dementia risk were observed between active and inactive profiles.</p><p><strong>Conclusions: </strong>This study highlights the important role of social and physical activity in simultaneously preventing fall, dementia, and their transitions, particularly among non-working individuals, including those on sick leave or retired.</p>","PeriodicalId":7516,"journal":{"name":"Alzheimer's Research & Therapy","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13366702/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148417992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Qiang Zhang, Jordan L Schultz, Jacob E Simmering, Braedon Q Kirkpatrick, Matthew A Weber, Sydney Skuodas, Tara Hicks, Grace Pierce, Margaret Laughlin, Benu George, Aimee X Bertolli, Travis Larson, Ramasamy Thangavel, Mayu Oya, David K Meyerholz, Georgina Aldridge, Jan Fassler, Nandakumar S Narayanan
{"title":"Glycolysis-enhancing α<sub>1</sub>-adrenergic antagonists have therapeutic potential in Alzheimer's disease.","authors":"Qiang Zhang, Jordan L Schultz, Jacob E Simmering, Braedon Q Kirkpatrick, Matthew A Weber, Sydney Skuodas, Tara Hicks, Grace Pierce, Margaret Laughlin, Benu George, Aimee X Bertolli, Travis Larson, Ramasamy Thangavel, Mayu Oya, David K Meyerholz, Georgina Aldridge, Jan Fassler, Nandakumar S Narayanan","doi":"10.1186/s13195-026-02135-z","DOIUrl":"10.1186/s13195-026-02135-z","url":null,"abstract":"<p><strong>Background: </strong>Terazosin (TZ) is widely prescribed for hypertension and benign prostatic hyperplasia. Recent studies suggest that TZ enhances glycolysis and may protect against neurodegenerative diseases.</p><p><strong>Methods: </strong>We tested the hypothesis that TZ is neuroprotective in Alzheimer's disease (AD) in a yeast model, a mouse model, and two human datasets.</p><p><strong>Results: </strong>We report four main results. First, TZ increased ATP levels in a Saccharomyces cerevisiae mutant with impaired metabolism, and reduced Amyloid-beta42 (Aβ42) aggregation. Second, in 5xFAD mice, TZ attenuated amyloid pathology and rescued cognitive impairments in spatial memory and interval timing. Third, in the Alzheimer's Disease Neuroimaging Initiative (ADNI) database, AD patients taking glycolysis-enhancing drugs had a slower progression of both cognitive dysfunction and metabolic neuroimaging biomarkers (18 F-fluorodeoxyglucose positron emission tomography (FDG-PET)). Finally, in the Merative Marketscan dataset, patients taking glycolysis-enhancing drugs had lower risks of developing AD.</p><p><strong>Conclusion: </strong>These data provide preliminary evidence that glycolysis-enhancing drugs have therapeutic potential in AD.</p>","PeriodicalId":7516,"journal":{"name":"Alzheimer's Research & Therapy","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13644072/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148417919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Chun-Ting Yang, James M Wilkins, Aaron S Kesselheim, Dae Hyun Kim, Kueiyu Joshua Lin
{"title":"Clinical outcomes after antipsychotic discontinuation in nursing home residents with dementia: a nationwide cohort study.","authors":"Chun-Ting Yang, James M Wilkins, Aaron S Kesselheim, Dae Hyun Kim, Kueiyu Joshua Lin","doi":"10.1186/s13195-026-02134-0","DOIUrl":"10.1186/s13195-026-02134-0","url":null,"abstract":"<p><strong>Background: </strong>Antipsychotic medications in people with dementia should be avoided or limited to treatment courses of fewer than 3-4 months. It is unknown whether discontinuation of long-term antipsychotic medications in this population can improve clinical outcomes. This study evaluated clinical outcomes associated with discontinuation of long-term antipsychotic medication use compared with continued use among individuals with dementia residing in nursing homes.</p><p><strong>Methods: </strong>This cohort study used Medicare claims data (2013-2022) linked to Minimum Data Set clinical assessment data. The study population included nursing home residents aged ≥ 65 with dementia who had used antipsychotic medications for more than 90 days. Individuals who discontinued antipsychotic medications (gap ≥ 60 days) were matched to continuers using incidence density sampling based on time since first prescription of antipsychotic medications. Propensity score matching was applied to adjust for 86 covariates. Study outcomes included all-cause hospitalization, specific rehospitalization reasons, and all-cause mortality. Hazard ratios (HRs) were estimated using Cox proportional hazards model, and rate differences (RDs) per 1,000 person-years were estimated using generalized linear models.</p><p><strong>Results: </strong>Two thousand one hundred eleven propensity score-matched pairs were included and followed for a median of 298 days. Antipsychotic medication discontinuation versus continuation was associated with lower risk of all-cause hospitalization (HR [95% CI]: 0.83 [0.72, 0.96]; RD [95% CI]: -55.85 [-97.82, -13.88]) and hospitalization for pneumonia (HR: 0.51 [0.29, 0.90]; RD: -12.85 [-23.26, -2.44]) or urinary tract infections (HR: 0.47 [0.26, 0.83]; RD: -14.22 [-24.62, -3.83]); non-significantly lower risks of hospitalization for falls (HR: 0.88 [0.70, 1.11]; RD: -13.19 [-37.78, 11.41]), delirium (HR: 0.76 [0.57, 1.02]; RD: -19.26 [-39.18, 0.66]), stroke (HR: 0.95 [0.42, 2.16]; RD: -0.31 [-7.06, 6.44]), and all-cause mortality (HR: 0.89 [0.79, 1.02]; RD: -38.23 [-81.01, 4.54]). Subgroup analyses showed the greatest reduction in hospitalization risk was among individuals with moderate-to-severe dementia (HR: 0.78 [95% CI: 0.65, 0.93]; RD: -96.76 [-163.75, -29.77]).</p><p><strong>Conclusions: </strong>Among nursing home residents with dementia, discontinuing long-term antipsychotic medication use was associated with lower risks of hospitalization, pneumonia, and urinary tract infections, suggesting clinical benefits in this population.</p>","PeriodicalId":7516,"journal":{"name":"Alzheimer's Research & Therapy","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13625465/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148395515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Tyler R Bell, Carol E Franz, Christine Fennema-Notestine, Erin E Sundermann, Shelby B Hughes, Matthew S Panizzon, Imanuel Lerman, Jeremy A Elman, William S Kremen
{"title":"Chronic pain as a risk factor for Alzheimer's disease pathology: a longitudinal ADNI study.","authors":"Tyler R Bell, Carol E Franz, Christine Fennema-Notestine, Erin E Sundermann, Shelby B Hughes, Matthew S Panizzon, Imanuel Lerman, Jeremy A Elman, William S Kremen","doi":"10.1186/s13195-026-02137-x","DOIUrl":"10.1186/s13195-026-02137-x","url":null,"abstract":"<p><strong>Background: </strong>Growing evidence supports chronic pain (CP) as a risk factor for Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). We examined whether CP is associated with longitudinal worsening of AD-related biomarkers, brain structure, and cognition, and whether effects differ by APOE-ε4 status.</p><p><strong>Methods: </strong>Data were drawn from 1,493 participants in the Alzheimer's Disease Neuroimaging Initiative (ADNI) without baseline dementia (mean age = 72.4 ± 7.19 years; 48% female). Linear mixed-effects models tested longitudinal change in cerebrospinal fluid (CSF) and positron emission tomography (PET) amyloid-β (Aβ) and phosphorylated tau (p-tau181), structural MRI indices (AD-related cortical signature, hippocampal and entorhinal volumes, precuneus thickness), and cognitive outcomes (episodic memory, executive function, Mini-Mental State Examination [MMSE]). Models included fixed effects of CP status, APOE-ε4 status, time (years since baseline), and their two-way and three-way interactions, adjusting for age, sex, education, baseline Aβ positivity status, and time-varying depressive symptoms.</p><p><strong>Results: </strong>At baseline, 30% of participants (n = 452) reported CP and 45% (n = 666) were APOE-ε4 carriers. CP and APOE-ε4 status did not independently predict baseline CSF Aβ42/Aβ40, PET Aβ burden, or CSF p-tau181. Longitudinally, the CP+/ε4 + group showed greater AD-like changes in CSF Aβ42/Aβ40 and CSF p-tau181, thinning of the precuneus (β=-0.09, p<.001) and faster decline in episodic memory (β=-0.08, p<.001), compared to all other groups. Many of these associations remained when excluding participants with MCI or restricting to Aβ-negative participants.</p><p><strong>Conclusions: </strong>The combination of CP and APOE-ε4 carriership was associated with greater longitudinal worsening of brain structure and cognitive function, even among individuals who were Aβ-negative at baseline. These findings provide in vivo evidence that CP is associated with greater AD-related worsening over time in the context of genetic susceptibility. As evidence accumulates, CP may warrant recognition as a risk factor in dementia prevention frameworks, though causal inferences require further study.</p>","PeriodicalId":7516,"journal":{"name":"Alzheimer's Research & Therapy","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13613787/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148381479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Erin K Murphy, Kathleen Hatch, Stephen Y Wise, Oluseyi O Fatanmi, Sarah A Petrus, Manish Bhomia, Daniela Lecca, Barbara E C Knollmann-Ritschel, Daniel P Perl, Vijay K Singh, Diego Iacono
{"title":"γ-radiation reduces phosphorylated-tau in rhesus macaque brains: potential implications for Alzheimer's disease and other tauopathies.","authors":"Erin K Murphy, Kathleen Hatch, Stephen Y Wise, Oluseyi O Fatanmi, Sarah A Petrus, Manish Bhomia, Daniela Lecca, Barbara E C Knollmann-Ritschel, Daniel P Perl, Vijay K Singh, Diego Iacono","doi":"10.1186/s13195-026-02128-y","DOIUrl":"10.1186/s13195-026-02128-y","url":null,"abstract":"<p><strong>Background: </strong>Studies on the effects of γ-radiation on nonhuman primate (NHP) brains are limited, despite the critical need to understand the impact of radiation exposure on the brain from various sources like radiotherapy equipment, space travel, and potential nuclear events.</p><p><strong>Methods: </strong>We investigated molecular and neuropathological changes in rhesus macaque brains after a single 5.8 Gy total-body γ-radiation exposure. We analyzed samples dissected from frontal cortex (FCtx), hippocampus (Hippo), and cerebellum (CRB) of irradiated (RAD) vs. unirradiated/control (CTRL) animals. Western blotting and digital PCR (dPCR) analyses were used to measure different phosphorylated-Tau (pTau) forms and neurodegeneration markers (i.e., amyloid protein precursor [APP], neurofilament-light chain [NFL], glial fibrillary acidic protein [GFAP], ionized calcium-binding adapter molecule 1 [IBA1/AIF1], and myelin basic protein [MBP]).</p><p><strong>Results: </strong>We detected lower levels of different forms of soluble pTau species (pTau181, and pTau217, among others) in RAD vs. CTRL animals across all three examined brain regions. While APP and GFAP levels were unchanged in the FCtx, increased IBA1 and NFL levels were detected alongside decreased MBP levels. Moreover, dPCR data identified decreased expression of GFAP and MBP in the FCtx. Importantly, the molecular changes observed were not accompanied by overt signs of neurodegeneration or cellular abnormalities upon neuropathological assessment.</p><p><strong>Conclusions: </strong>These findings in irradiated NHPs' brains are novel and indicate that a single total-body γ-radiation exposure significantly alters soluble pTau levels after a few weeks from irradiation without causing obvious neurohistological damage. These results open intriguing new possibilities of exploring γ-radiation-based strategies to modulate the progression of tauopathies, including Alzheimer's disease.</p>","PeriodicalId":7516,"journal":{"name":"Alzheimer's Research & Therapy","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13595805/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148366619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Inge M W Verberk, Lotte A de Koning, Emma M Coomans, Calvin Trieu, Anna E Leeuwis, Jacob Hunter, Lee Honigberg, Wiesje M van der Flier, Everard G B Vijverberg, Rik Ossenkoppele, Elsmarieke van de Giessen, Charlotte E Teunissen
{"title":"The potential of key Alzheimer's plasma biomarkers to mimic tau PET MUBADA-based disease staging.","authors":"Inge M W Verberk, Lotte A de Koning, Emma M Coomans, Calvin Trieu, Anna E Leeuwis, Jacob Hunter, Lee Honigberg, Wiesje M van der Flier, Everard G B Vijverberg, Rik Ossenkoppele, Elsmarieke van de Giessen, Charlotte E Teunissen","doi":"10.1186/s13195-026-02085-6","DOIUrl":"10.1186/s13195-026-02085-6","url":null,"abstract":"<p><strong>Background: </strong>Patients with Alzheimer's disease (AD) with a low to intermediate tau-PET burden might benefit most from anti-amyloid treatment. Staging tau burden with plasma biomarkers would offer a scalable alternative to staging with tau-PET. This study investigated whether key plasma biomarkers P-tau217, P-tau181, Aβ42/40, GFAP and NfL can be used to accurately stage amyloid status (A-/A+) and tau-PET burden, and evaluated the relation of such a plasma-based staging system with cognitive outcomes over time.</p><p><strong>Methods: </strong>We included 105 participants with subjective cognitive decline (n = 27 A-, n = 18 A+), A+ mild cognitive impairment (n = 10) or A + AD-dementia (n = 50) from the Amsterdam Dementia Cohort who underwent [<sup>18</sup>F]flortaucipir PET-burden assessment (T<sub>low</sub>, T<sub>intermediate</sub> or T<sub>high</sub>; based on MUBADA SUVr) and longitudinal cognitive assessment (average follow-up: 4.1 ± 3.5 years). AD-related plasma biomarkers were measured with Simoa. Discriminative performance (AUC) of each marker was compared using ROC analysis, and combined utility was assessed with logistic regression. Subsequently, cutoffs were established aiming for 90%-specificity, to regroup participants into a plasma-based staging scheme. Age-, sex- and education-adjusted linear mixed models (LMM) were performed to compare associations of plasma versus PET-based staging with longitudinal cognition.</p><p><strong>Results: </strong>27 participants were A-T<sub>PET_low</sub>, 22 A+T<sub>PET_low</sub>, 27 A+T<sub>PET_int</sub> and 29 A+T<sub>PET_high</sub>. To discriminate A-T<sub>PET_low</sub> participants from A+T<sub>PET_low/int</sub> participants, P-tau217 performed best among all measured markers P-tau217, P-tau181, Aβ42/40, GFAP and NfL (AUC = 0.92 [95% CI: 0.856-0.985]). To discriminate A+T<sub>PET_high</sub> participants from A+T<sub>PET_low/int</sub> participants, also P-tau217 performed best among all markers (AUC = 0.74 [95% CI: 0.618-0.862]). A combination of Wald's backward-selected plasma markers did not statistically improve discriminative performance (DeLong's p > 0.05; two-marker combinations selected). Applying two cutoffs for P-tau217 as well as for the two-marker combinations, at 90% specificity to discriminate subsequent groups, we derived two plasma-based staging schemes. While the tau-PET staging scheme significantly and consistently associated with cognitive performance and decline across cognitive domains in LMMs, the plasma staging schemes did not.</p><p><strong>Conclusions: </strong>Performance of plasma-based staging approaches developed in this study were high when discriminating individuals without amyloid pathology, while this was moderate when discriminating amyloid positive individuals with a high tau-PET burden. Our LMM findings visualize that tau staging in amyloid-positive individuals remains optimally performed with tau-PET scans.</p>","PeriodicalId":7516,"journal":{"name":"Alzheimer's Research & Therapy","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13591876/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148358991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Smoking cessation duration and risk of Alzheimer's disease: a nationwide cohort study in Korea.","authors":"Seong-Ho Moon, Min-Ho Kim, Jae-Hong Ryoo","doi":"10.1186/s13195-026-02132-2","DOIUrl":"10.1186/s13195-026-02132-2","url":null,"abstract":"<p><strong>Background: </strong>Smoking is a modifiable risk factor for Alzheimer's disease, yet the temporal pattern of risk reduction following smoking cessation remains unclear. We investigated whether Alzheimer's disease risk declines according to the duration of sustained smoking cessation in a large nationwide cohort.</p><p><strong>Methods: </strong>Using the Korean National Health Insurance Service database (2002-2023), we identified 1,403,636 adults with stable longitudinal smoking patterns based on repeated biennial health examinations. Smoking status was classified as never smokers, current smokers, or sustained quitters, with cessation duration categorised into 2-year intervals (< 2, 2-3, 4-5, 6-7, ≥ 8 years). Incident Alzheimer's disease was defined as at least two separate NHIS insurance claims. Cox proportional hazards models were used to estimate hazard ratios and 95% confidence intervals, adjusting for demographic, lifestyle, and metabolic factors.</p><p><strong>Results: </strong>During a mean follow-up of 10.5 years, 58,519 incident Alzheimer's disease cases were identified. Compared with current smokers, sustained quitters exhibited progressively lower hazards of Alzheimer's disease with increasing duration of abstinence, demonstrating a dose-response pattern. Individuals who had quit for < 2 years showed a risk reduction relative to current smokers (adjusted HR 0.899; 95% CI 0.819-0.986), while those with ≥ 8 years of abstinence had substantially lower risk (adjusted HR 0.582; 95% CI 0.423-0.801). When referenced to never smokers, those with < 2 years of abstinence retained excess risk, whereas cessation for ≥ 2 years was associated with Alzheimer's disease risk approaching that of never smokers.</p><p><strong>Conclusions: </strong>Sustained smoking cessation was associated with a graded reduction in Alzheimer's disease risk, with approximately 2 years of abstinence needed to approach never-smoker risk.</p>","PeriodicalId":7516,"journal":{"name":"Alzheimer's Research & Therapy","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13591907/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148349953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Noa Bregman, Nuno Pedrosa de Barros, Talya Nathan, Mori Hay Levy, Diana Sima, Simon Van Eyndhoven, Aya Bar-David, Orna Aizenstein, Dana Niry, Lilian Atlan, Anan Abu Awad, Elissa Ash, Nurit Omer, Tamara Shiner
{"title":"Lecanemab in practice: AI-derived MRI predictors of benefit and Amyloid Related Imaging Abnormalities (ARIA).","authors":"Noa Bregman, Nuno Pedrosa de Barros, Talya Nathan, Mori Hay Levy, Diana Sima, Simon Van Eyndhoven, Aya Bar-David, Orna Aizenstein, Dana Niry, Lilian Atlan, Anan Abu Awad, Elissa Ash, Nurit Omer, Tamara Shiner","doi":"10.1186/s13195-026-02127-z","DOIUrl":"10.1186/s13195-026-02127-z","url":null,"abstract":"<p><strong>Introduction: </strong>Lecanemab, a monoclonal antibody targeting amyloid beta, has demonstrated meaningful clinical benefits in early Alzheimer's disease (AD), yet real-world data is needed to optimize patient selection and enhance safety monitoring, particularly with respect to amyloid-related imaging abnormalities (ARIA). Integration of quantitative and AI-derived MRI biomarkers may improve risk stratification and prediction of clinical trajectory.</p><p><strong>Methods: </strong>We conducted a retrospective real-world study of eighty-two patients with biomarker-confirmed early AD who initiated lecanemab at Tel Aviv Sourasky Medical Center between November 2023 and June 2025. Baseline MRI included volumetric T1-weighted imaging and susceptibility-weighted imaging (SWI). Automated whole-brain, regional cortical, and hippocampal volumes, and percentiles were extracted using FDA-cleared AI tools (icobrain by icometrix). Microhaemorrhage (MH) burden was assessed by both human and AI-assisted reads. Cognitive outcomes were evaluated using change in Mini-Mental State Examination (MMSE). Linear regression models assessed MRI predictors of cognitive response, and multivariable logistic regression identified predictors of ARIA.</p><p><strong>Results: </strong>Patients exhibited significantly lower cerebral volumes at treatment initiation. Mean whole brain percentile, mean gray-matter (GM) percentile, and mean white matter percentile were 11.45%, 8.6% and 38% respectively. Higher baseline GM volume predicted less MMSE decline at 12 months (β = 0.64, FDR-corrected p < 0.003). Hippocampal and white-matter volumes were not associated with cognitive outcomes. Seventeen patients (20.7%) developed ARIA. Baseline MH burden was the strongest predictor of ARIA (human rated OR=3.48 per MH, p=0.015, icobrain rated OR=3.25, p=0.01), while APOE ε4 carriage showed a strong directional trend which did not reach significance. Aspirin use and hypertension were not associated with ARIA. Agreement between icobrain and experts for MH ratings was excellent with a single-measure intraclass correlation coefficient (ICC) of 0.89 (95% CI: 0.83-0.93).</p><p><strong>Conclusions: </strong>AI-derived MRI markers, particularly GM volume and MH burden, provide valuable predictors of cognitive response and ARIA risk in patients treated with lecanemab. Integrating quantitative neuroimaging into clinical workflows may enhance personalized treatment decisions and improve real-world implementation of Amyloid-targeting therapies.</p>","PeriodicalId":7516,"journal":{"name":"Alzheimer's Research & Therapy","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13591922/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148350306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Wenshan Sun, Rong Xing, Jian Zhou, Yong Li, Gelin Xu
{"title":"Facial phenotypes in Alzheimer's disease: from neurobiology to artificial intelligence.","authors":"Wenshan Sun, Rong Xing, Jian Zhou, Yong Li, Gelin Xu","doi":"10.1186/s13195-026-02129-x","DOIUrl":"10.1186/s13195-026-02129-x","url":null,"abstract":"<p><p>Facial analysis is increasingly being explored as a source of scalable behavioral signals relevant to Alzheimer's disease (AD) and AD-related cognitive impairment. In this narrative review, informed by a structured literature search, we summarize current evidence on the biological and behavioral basis of facial alterations in AD, with particular emphasis on affective expressivity, neuropsychiatric manifestations, and dynamic facial behavior. We also review representative artificial intelligence-based facial analysis methods, including commonly used datasets, feature representations, and modeling strategies, ranging from facial landmarks and texture descriptors to spatiotemporal video models, multimodal fusion, and language-enhanced frameworks. Current evidence remains limited by small and largely single-center cohorts, heterogeneity in acquisition settings and outcome definitions, inadequate control of confounding factors, limited external validation, poor calibration reporting, and persistent concerns regarding interpretability and clinical specificity. Within the evolving biomarker-based diagnostic framework of AD, facial analysis is better viewed as a candidate, non-specific, and context-dependent tool for auxiliary risk stratification, triage support, and longitudinal monitoring rather than as stand-alone diagnostic tests. Future progress will depend on standardized data acquisition, integration with clinical and biomarker data, improved explainability, and prospective real-world validation.</p>","PeriodicalId":7516,"journal":{"name":"Alzheimer's Research & Therapy","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13591852/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148343716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}